Antibody specificity and characterisation
In this section
- Antibody specificity and characterisation
- Biomarker discovery and quantification
- Drug target discovery
- Glycan arrays and glycomics
- Human Proteome Array
- Label-free (SPRi)
- Reverse Phase Protein Array
- Small molecule microarrays
- Spatial transcriptomics
Antibody specificity and characterisation
Antibodies are vital research tools, but unless properly validated they can yield inconsistent data, wasting time, money and valuable samples.
Arrayjet customers have utilised protein microarray to independently validate thousands of antibodies against cross-reactivity and batch-to-batch variation.
High-density antigen microarrays for the assessment of antibody selectivity and off-target binding
R. Sjoberg, E. Andersson, C. Hellstrom, C. Mattsson, J. M. Schwenk, P. Nilsson, and B. Ayoglu
Methods in Molecular Biology
"Our Arrayjet Marathon has been instrumental in achieving the throughput and reliability that have been needed for the production of antigen arrays for validation of 47,000 antibodies within the Human Protein Atlas. It has also shown to be highly suitable for the production of our large-scale arrays that comprise over 20,000 features per array in both antigen and reverse phase serum arrays. We have arrayed more than 12,000 slides with the Arrayjet Marathon over the last five years and it has become a very important part of our research group and the SciLifeLab National Affinity Proteomics protein array facility."
Peter Nilsson, Principal Investigator, The Human Protein Atlas, Stockholm
Epitopes are the binding sites of antibodies, and characterisation can aid in the discovery and design of novel therapeutic drugs and vaccines.
By elucidating the mechanism of action, epitope mapping methods can assist the development of monoclonal antibodies. Peptide arrays are therefore a useful tool for high-throughput monoclonal antibody screening.
Epitope mapping of a monoclonal antibody directed against Neisserial heparin binding antigen using next generation sequencing of antigen-specific libraries
M. Domina, V. L. Cariccio, S. Benfatto, M. Venza, I. Venza, D. Donnarumma, E. Bartolini, E. Borgogni, M. Bruttini, L. Santini, A. Midiri, R. Galbo, L. Romeo, F. Patanè, C. Biondo, N. Norais, V. Masignani, G. Teti , F. Felici, and C. Beninati
Human protective response induced by meningococcus B vaccine is mediated by the synergy of multiple bactericidal epitopes
M. Giuliani, E. Bartolini, B. Galli, L. Santini, P. Lo Surdo, F. Buricchi, M. Bruttini, B. Benucci, N. Pacchiani, L. Alleri, D. Donnarumma, W. Pansegrau, I. Peschiera, I. Ferlenghi, R. Cozzi, N. Norais, M. M. Giuliani, D. Maione, M. Pizza, R. Rappuoli, O. Finco, and V. Masignani
Nature Scientific Reports
Phage display revisited: Epitope mapping of a monoclonal antibody directed against Neisseria meningitidis adhesin A using the PROFILER technology
V. L. Cariccio, M. Domina, S. Benfatto, M. Venza, I. Venza, A. Faleri, M. Bruttini, E. Bartolini, M. M. Giuliani, L. Santini, B. Brunelli, N. Norais, E. Borgogni, A. Midiri, R. Galbo, L. Romeo, C. Biondo, V. Masignani, G. Teti, F. Felici, and C. Beninati
"We are glad to have found a dedicated partner that accepted the specific challenges of our regulated production environment and developed an instrument tailored to our needs.”
Dr. Dr Holger Wenschuh, CEO, JPT Peptide Technologies
Hybridoma technology is key to producing large numbers of monoclonal antibodies. Screening by ELISA uses costly reagents and is time-consuming, and protein microarray offers a reliable high-throughput solution.
New monoclonal antibodies to defined cell surface proteins on human pluripotent stem cells
C. M. O'Brien, H. S. Chy, Q. Zhou, S. Blumenfeld, J. W. Lambshead, X. Liu, J. Kie, B. D. Capaldo, T. Chung, T. E. Adams, T. Phan, J. D. Bentley, W. J. McKinstry, K. Oliva, P. J. McMurrick, Y. Wang, F. J. Rossello, G. J. Lindeman, D. Chen, T, Jarde, A. T. Clark, H. E. Abud, J. E. Visvader, C. M. Nefzger, J. M. Polo, J. F. Loring, and A. L. Laslett
"We are very pleased to be working with Arrayjet, as we see high throughput inkjet technology as very much the future of protein microarrays. The Super-Marathon enables us to do things that are simply not possible with a pin spotter, and we've given it pride of place in our new, highly automated facility."
Alan Sawyer, previous Director at EMBL Monoclonal Core Facility